Diabetes drug ‘increases heart failure risk’
August 21st, 2009 - 1:33 pm ICT by ANILondon, Aug 21 (ANI): Commonly prescribed diabetes drug increases the risk of heart failure compared with a similar medication, says a new study.
The research, published on bmj.com, has concluded that rosiglitazone is associated with an increased risk of heart failure and death among older patients compared to pioglitazone.
Both the drugs belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes. They help to control blood sugar levels, but both drugs can also cause side effects including weight gain, fluid retention and heart failure.
It is not clear whether there are clinically important differences in the cardiac safety of these two drugs, so researchers in Canada compared the risk of heart attack, heart failure and death in patients treated with rosiglitazone and pioglitazone.
With the help of prescription records, boffins identified nearly 40,000 patients aged 66 years and older who started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008.
Data on hospital admission for either a heart attack or heart failure during the six-year study period were recorded and deaths were identified from a national database.
Detailed analysis showed that patients treated with pioglitazone had a significantly lower risk of heart failure and death compared to patients treated with rosiglitazone, but there was no significant difference in the risk of heart attack.
The researchers estimate that, for every 93 patients treated with rosiglitazone rather than pioglitazone, one additional cardiovascular event or death would be predicted to occur annually.
“Our findings suggest clinically important differences in the cardiovascular safety profiles of rosiglitazone and pioglitazone in clinical practice,” say the authors.
“Given the accumulating evidence of harm with rosiglitazone treatment and the lack of a distinct clinical advantage for the drug over pioglitazone, it is reasonable to question whether ongoing use of rosiglitazone is justified,” they conclude. (ANI)
- Drug used to treat type 2 diabetes linked to heart problems - Mar 18, 2011
- No link between diabetes drug and rise in heart attacks - Jun 30, 2010
- Popular diabetes drugs could elevate risk of heart failure and death - Dec 04, 2009
- Diabetes drug may boost power of anti-depressants - May 03, 2012
- Heart risks linked to diabetes drug - Jun 29, 2010
- Popular diabetes drugs 'increase risk for fractures in patients' - Jul 30, 2010
- Diabetes medication safe for Alzheimer's patients - Sep 14, 2010
- Diabetes drug can raise heart disease risk by 25 percent - Mar 18, 2011
- Some diabetes drugs are better than others: Study - Apr 07, 2011
- The Diabetes Drugs, Avandia and Actos, Have The Same Amount of Risks - Aug 29, 2010
- Diabetes or lipid-lowering medications may help treat addiction - Apr 06, 2011
- BP drug not tied to death risk among heart patients - Apr 11, 2012
- Bariatric surgery cuts long-term cardiovascular risk in diabetics - Mar 31, 2011
- Common painkillers increase risk of heart problems: Study - Jan 12, 2011
- Certain diabetes drugs double heart failure risk - Aug 29, 2008
Tags: blood sugar levels, cardiovascular event, clinical advantage, diabetes drug, evidence of harm, fluid retention, heart attack, heart failure, heart failure risk, hospital admission, increases heart, national database, prescription records, risk of heart attack, rosiglitazone, safety profiles, study period, treatment of type 2 diabetes, type 2 diabetes, weight gain